PRIP Scheme: Boosting Pharma & MedTech Innovation in India
India’s strength in pharmaceuticals and medical technology has long been in manufacturing affordable products for the world. Now, the PRIP Scheme (Promotion of Research & Innovation in Pharma–MedTech Sector) aims to take the country from “Make in India” to “Innovate in India.”
What is the PRIP Scheme?
Launched by the Department of Pharmaceuticals (DoP), Government of India, PRIP has a total outlay of ₹5,000 crore (FY 2023-24 to FY 2028-29) to strengthen R&D and innovation.
It has two parts:
- Component A: Establishes Centres of Excellence (CoEs) at NIPERs to boost research infrastructure.
- Component B: Funds industry-led R&D projects across six key areas—new drugs, biologics, precision medicine, medtech, orphan drugs, and antimicrobial resistance.
Who Can Apply
Pharma and MedTech companies, startups, and academia can apply. Funding support ranges up to ₹125 crore for large projects and ₹1 crore for startups and MSMEs at the proof-of-concept stage.
Why It Matters
The PRIP Scheme could transform India’s role from being the “pharmacy of the world” to a global innovation hub. It encourages collaboration between industry and academia, reduces import dependence, and supports the development of advanced therapies and devices.
The Road Ahead
If implemented well, PRIP will help India capture more value in global health markets and accelerate the shift toward high-tech, innovation-driven growth.
In short, PRIP is India’s push to discover, design, and deliver the next generation of medical breakthroughs.
Leave a Reply